www.statnews.com Open in urlscan Pro
2606:4700::6812:1dcd  Public Scan

Form analysis
2 forms found in the DOM

GET https://www.statnews.com/

<form class="header-search search-form" role="search" method="get" action="https://www.statnews.com/">
  <input type="search" class="search-form-field" placeholder="Search …" value="" name="s" aria-label="Search …">
  <button type="submit" class="header-btn header-btn-search">Search</button>
</form>

Name: modal — POST /wp-json/stat-hubspot/v1/signup

<form class="stat-hubspot-signup stat-form" method="post" action="/wp-json/stat-hubspot/v1/signup" name="modal">
  <div class="stat-hubspot-signup-fields">
    <div class="stat-form-full">
      <div class="stat-form-brand">
        <img loading="lazy" decoding="async" src="https://www.statnews.com/wp-content/uploads/2023/06/DC-Diagnosis-Logo-Black.png" alt="D.C. Diagnosis" class="stat-form-brand-logo" width="700" height="120">
        <p class="stat-form-brand-description">Washington never stops. Cut through the noise with our essential updates on health care politics and policy</p>
      </div>
      <input type="email" name="email" required="" placeholder="Email Address">
      <div class="stat-form-select-wrapper">
        <select name="industry_internal_" class="has-faux-placeholder is-empty" aria-label="Industry">
          <option value="" selected="">Industry</option>
          <option value="Academia">Academia</option>
          <option value="Advertising/Communications Agency">Advertising/Communications Agency</option>
          <option value="Advocacy/Non-Profit">Advocacy/Non-Profit</option>
          <option value="Banking">Banking</option>
          <option value="Biotech">Biotech</option>
          <option value="Clinical Research Organization">Clinical Research Organization</option>
          <option value="Consulting Firm">Consulting Firm</option>
          <option value="Consumer Health">Consumer Health</option>
          <option value="Financial Services (Other)">Financial Services (Other)</option>
          <option value="Government">Government</option>
          <option value="Healthcare Payer/Insurance">Healthcare Payer/Insurance</option>
          <option value="Health Tech">Health Tech</option>
          <option value="Hospital Systems/Provider">Hospital Systems/Provider</option>
          <option value="Law">Law</option>
          <option value="Media">Media</option>
          <option value="Medical Devices">Medical Devices</option>
          <option value="Medical Technology">Medical Technology</option>
          <option value="Pharmaceuticals">Pharmaceuticals</option>
          <option value="Pharmacy/Retail">Pharmacy/Retail</option>
          <option value="Real Estate">Real Estate</option>
          <option value="Trade Association">Trade Association</option>
          <option value="Technology">Technology</option>
          <option value="Venture Capital">Venture Capital</option>
        </select>
      </div>
      <input type="submit" class="stat-button-primary" value="Sign up for our newsletter">
      <span class="privacy-link"><a href="/privacy/" target="_blank" rel="noopener noreferrer">Privacy Policy</a></span>
      <input type="hidden" name="stat_newsletters_source" value="bc_modal">
      <input type="hidden" name="stat_newsletters_campaign" value="">
      <input type="hidden" name="lists[stat_newsletters]" value="dc_diagnosis">
    </div>
  </div>
  <div class="stat-hubspot-signup-response"></div>
</form>

Text Content

Skip to Main Content
H5N1 Bird Flu
advocacy
research
 How are GLP-1 drugs changing science, business & health care? Learn more 
 * Newsletters
 * Log In
 * My Account
 * Subscribe Now

My Account
 * Settings
 * Billing
 * Log In

Reporting from the frontiers of health and medicine
 * Newsletters
 * Log In
 * My Account
 * Subscribe Now

 * Biotech
 * Pharma
 * Public Health
 * Health Tech
 * Policy
 * Science
 * First Opinion
 * STAT+
 * STAT Events
 * 


Search
 * Log In
 * Subscribe Now
 * My Account

Home

News
 * Latest
 * Business
   * Biotech
   * Pharma
   * Health Tech
   * Health Insurance
   * Hospitals
   * Medical Devices
 * Washington
   * Policy
   * FDA
   * CDC
   * NIH
 * Science
   * CRISPR
   * Gene Therapy
   * Research
   * Neuroscience

 * Public Health
   * Addiction
   * Covid-19
   * Abortion
   * Health Disparities
   * Infectious Disease
   * Mental Health
 * Disease
   * Cancer
   * Cardiovascular Disease
   * Chronic Disease
   * Diabetes
   * Dementia
   * Obesity
 * Features
   * The Obesity Revolution
   * Living With
   * The War on Recovery

Newsletters
Opinion
Columns
 * Adam Feuerstein
 * Matthew Herper
 * Jennifer Adaeze Okwerekwu
 * Ed Silverman

Reports
E-books
Podcasts
Tools & Trackers
 * CRISPR Trackr
 * Breakthrough Device Tracker
 * Generative AI Tracker
 * Obesity Drug Tracker

Events
 * Breakthrough Summit West
 * 2024 STAT Summit

Community
 * 2024 STATUS List
 * STAT Madness

Video
Advertise
 * STAT Brand Studio

Don't miss out

Subscribe to STAT+ today, for the best life sciences journalism in the industry

Learn more


 * YOUR GO-TO SOURCE
   
   for the latest news and insights in the world of life sciences, medicine,
   biotech, and pharma

 * JOIN THE CONVERSATION
   
   at exclusive live and virtual events hosted by STAT

 * STAY AHEAD
   
   with subscriber-only newsletters delivered to your inbox daily

 * MAKE DATA-DRIVEN DECISIONS
   
   with our premium data tools

 * 


YOU'VE BEEN SELECTED!

Get Started Cancel Anytime

 * YOUR GO-TO SOURCE
   
   for the latest news and insights in the world of life sciences, medicine,
   biotech, and pharma

 * JOIN THE CONVERSATION
   
   at exclusive live and virtual events hosted by STAT

 * STAY AHEAD
   
   with subscriber-only newsletters delivered to your inbox daily

 * MAKE DATA-DRIVEN DECISIONS
   
   with our premium data tools

 * 


GET UNLIMITED ACCESS!

Get Started Cancel Anytime

 * YOUR GO-TO SOURCE
   
   for the latest news and insights in the world of life sciences, medicine,
   biotech, and pharma

 * JOIN THE CONVERSATION
   
   at exclusive live and virtual events hosted by STAT

 * STAY AHEAD
   
   with subscriber-only newsletters delivered to your inbox daily

 * MAKE DATA-DRIVEN DECISIONS
   
   with our premium data tools

 * 


YOU'VE BEEN SELECTED!

Get started Cancel anytime

 * YOUR GO-TO SOURCE
   
   for the latest news and insights in the world of life sciences, medicine,
   biotech, and pharma

 * JOIN THE CONVERSATION
   
   at exclusive live and virtual events hosted by STAT

 * STAY AHEAD
   
   with subscriber-only newsletters delivered to your inbox daily

 * MAKE DATA-DRIVEN DECISIONS
   
   with our premium data tools

 * 


GET UNLIMITED ACCESS!

Get started Cancel anytime
Politics


GROCERS ARE PUSHING LEGISLATION THEY CLAIM WOULD ENHANCE FOOD SAFETY. ADVOCATES
SAY IT WOULD GUT FDA RULES

 * 

By Nicholas Florko April 16, 2024

Reprints
 * 
 * 
 * 
 * 
 * 
 * 
 * 

Empty freezer shelves in a grocery store after a foodborne illness outbreak
traced to ice cream contaminated with listeria. Jamie Squire/Getty Images
 * 
 * 
 * 
 * 
 * 
 * 
 * 

WASHINGTON — In the last decade, Americans have been sickened by salmonella from
cucumbers, listeria from Mexican-style cheese, and E. coli from romaine lettuce.
Now, it would seem that Washington is finally getting serious about making sure
the Food and Drug Administration has the power to promptly investigate and
respond to foodborne outbreaks.

Last month, a bipartisan group of lawmakers in the House introduced the “Food
Traceability Enhancement Act.” The lobby representing food retailers has
applauded the bill, claiming it “enhances food safety.”

advertisement



There’s just one problem: The bill, according to experts, does the opposite. It
would carve grocers, restaurants, and food warehouses out of a major portion of
the FDA’s rules, which are meant to help regulators quickly track down the cause
of a foodborne outbreak, and it would delay enforcement of the entire food
safety program, slated to begin in 2026, by several years.

STAT+ Exclusive Story

Already have an account? Log in


THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS


UNLOCK THIS ARTICLE — PLUS DAILY INTELLIGENCE ON CAPITOL HILL AND THE LIFE
SCIENCES INDUSTRY — BY SUBSCRIBING TO STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe
Log In
 * 
 * 
 * 
 * 
 * 
 * 
 * 


ABOUT THE AUTHOR REPRINTS


NICHOLAS FLORKO

Reporter, Commercial Determinants of Health

Nicholas Florko reports on the commercial determinants of health.


nicholas.florko@statnews.com

@NicholasFlorko


TAGS

Congress

FDA

STAT+

STAT encourages you to share your voice. We welcome your commentary, criticism,
and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.


GET UNLIMITED ACCESS TO THE LATEST NEWS AND EXCLUSIVE ANALYSIS.

Subscribe now


CATCH UP ON THE LATEST MUST-READ COVERAGE AND ANALYSIS

Read Now

advertisement





advertisement





TRENDING

Early tests of H5N1 prevalence in milk suggest U.S.…
Early tests of H5N1 prevalence in milk suggest U.S. bird flu outbreak in cows is
widespread

Takeda is fourth big company to leave BIO since…
Takeda is fourth big company to leave BIO since December

Massive amounts of H5N1 vaccine would be needed if…
Massive amounts of H5N1 vaccine would be needed if there’s a bird flu pandemic.
Can we…



RECOMMENDED

Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex…
Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South
Africa, and more

Mental health crisis centers and EmPATH units: offering care…
Mental health crisis centers and EmPATH units: offering care that busy ERs can’t

Vertex offers limited access to a cystic fibrosis drug…
Vertex offers limited access to a cystic fibrosis drug in South Africa — and may
undercut…



RECOMMENDED STORIES

Exclusive John Wilkerson


STAT PLUS: TAKEDA IS FOURTH BIG COMPANY TO LEAVE BIO SINCE DECEMBER

Hospitals Liz Kowalczyk — Boston Globe


STAT PLUS: ‘DEVALUED, DISEMPOWERED, AND UNSEEN’: MASS GENERAL BRIGHAM DOCTORS
REACT TO LATEST MERGER STEP

advertisement


In the Lab Theresa Gaffney


STAT PLUS: NIH POSTDOCS WILL GET A RAISE NEXT YEAR — BUT NOT AS MUCH AS THEY
HOPED

Pharmalot Ed Silverman


STAT PLUS: NEW ANTIBIOTICS WERE UNDERPRESCRIBED FOR HARD-TO-TREAT INFECTIONS,
STUDY FINDS

Exclusive Annalisa Merelli


STAT PLUS: HOW A SCIENTIFIC SLIP-UP CAUSED A PREGNANT WOMAN TO GET AN UNTESTED
TREATMENT FOR PRETERM BIRTH

Washington never stops. Cut through the noise with our essential updates on
health care politics and policy

Industry Academia Advertising/Communications Agency Advocacy/Non-Profit Banking
Biotech Clinical Research Organization Consulting Firm Consumer Health Financial
Services (Other) Government Healthcare Payer/Insurance Health Tech Hospital
Systems/Provider Law Media Medical Devices Medical Technology Pharmaceuticals
Pharmacy/Retail Real Estate Trade Association Technology Venture Capital
Privacy Policy


Reporting from the frontiers of health and medicine

Back to top

Company

 * About
 * Our Team
 * Contact Us
 * Careers
 * Diversity & Inclusion
 * Our Awards
 * Advertise With Us
 * STAT Brand Studio
 * Supporters
 * Licensing Stories

Account

 * STAT+
 * Group Subscriptions
 * FAQ
 * My Account
 * Log In
 * Subscribe

More

 * Events
 * Newsletters
 * Reports
 * App
 * Podcasts
 * Community

 * Privacy
 * Comment Policy
 * Terms
 * Do Not Sell My Data
 * ©2024 STAT

 * 
 * 
 * 
 * 
 * 
 * 
 * 

 

Become a STAT+ subscriber today!

Become a STAT+ subscriber today!

Unlimited access to essential biotech, medicine, and life sciences journalism

Get started

Become a STAT+ subscriber today!

Become a STAT+ subscriber today!

Your go-to source for the latest news and insights on biopharma and the life
sciences

Get started

Become a STAT+ subscriber today!

Become a STAT+ subscriber today!

Unlimited access to essential biotech, medicine, and life sciences journalism

Get started

Become a STAT+ subscriber today!

Become a STAT+ subscriber today!

Your go-to source for the latest news and insights on biopharma and the life
sciences

Get started